Emina Karahmet1*, Besim Prnjavorac2, Tamer Bego3, Neven Meseldžić3, Selma Imamović3, Esma Karahmet4, Farooq Sher5, Lana Lekić6 and Edin Begić7
1Department of Biochemistry and Molecular Biology, University of Tuzla, Faculty of Pharmacy, Tuzla, Bosnia and Herzegovina
2Department of Pathophysiology, University of Sarajevo, Faculty of Pharmacy, Sarajevo, Bosnia and Herzegovina
3Department of Biochemistry and Clinical Analysis, University of Sarajevo, Faculty of Pharmacy, Sarajevo, Bosnia and Herzegovina
4Department of Food and Nutrition Research, Juraj Strossmayer University of Osijek, Faculty of Food Technology, Croatia
5Department of Engineering, School of Science and Technology, Nottingham Trent University, Nottingham NG11 8NS, United Kingdom
6Department of Pharmacology and Clinical Pharmacy, University of Modern Sciences, Faculty of Pharmacy, Bosnia and Herzegovina
7Department of Pharmacology, Sarajevo School of Science and Technology, Sarajevo, Bosnia and Herzegovina
*Corresponding Author:Emina Karahmet, Department of Biochemistry and Molecular Biology, University of Tuzla, Faculty of Pharmacy, Tuzla, Bosnia and Herzegovina.
Received: June 22, 2021; Published: August 07, 2021
The aim of this research study was to compare interleukin 1β (IL-1β) levels in participants with diabetes mellitus 2 (DM2) depending on the duration of disease and comorbidity.
Methods: A total number of 150 participants were observed by two different ways. In a first observation, all participants were grouped into four different groups (A, B, C, K), with criteria duration of DMT2: A- less than 10, B- 10-20, C- 20-30 years of DMT2 duration. Second observation was conducted with criteria accompanied comorbidities of DMT2, and all participants were grouped into 5 different groups (1: DMT2+ polyneuropathy (PNP) + hypertension, 2: DMT2 + PNP, 3: DMT2 + hypertension, 4: DM, 5: control). Each group included 30 participants, except group A in first observation that included 60 participants. Control group included 30 healthy participants. An enzyme-linked immunosorbent assay (ELISA) was performed to measure IL-1β levels in each group.
Results: In the first evaluation, IL-1β of the group C (98.43 pg/ml ± 5.72) was at a significantly lower level compared to group A 113.49 pg/mL ± 5.29 and B 114.53 pg/ml ± 5.69, and was not significantly different than control group K 98.88 pg/ml ± 14.42 (p = 0.002). IL-1β in group A was significantly different to group K, p = 0.0001, and group B was significantly different to group K, p = 0.003. IL-1β did not show a significant correlation with diabetic polyneuropathy.
In the second evaluation, IL-1β (pg/ml) was significantly different in groups (p < 0.001) with average ranges per groups: group 1: 93.84, group 2: 63.76, group 3: 86.69, group 4: 69.42 and group 5: 47.97. Groups 1 and 2 were significantly different (40.09 vs. 27.29, p = 0.007), groups 1 and 5 were significantly different (45.97 vs. 22.03, p < 0.001) and groups 3 and 5 show significant difference between each other (38.96 vs. 22.94, p < 0.001).
Conclusion: Hypertension has bigger impact to IL-1β ranges than diabetic neuropathy, but showed that hypertension and neuropathy are correlated and will probably be risk factors for the manifestation of another comorbidity in diabetic participants.
Keywords: Interleukins; Inflammation; Diabetes Mellitus; Hypertension; Diabetic Neuropathy
Citation: Emina Karahmet., et al. “IL-1β in Correlation to the Common Diabetic Complications”.Acta Scientific Medical Sciences 5.9 (2021): 25-29.
Copyright: © 2021 Emina Karahmet., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.